

Press Release

16 November 2010

GETTING DATA FASTER: A NEW AUSTRALASIAN PARADIGM



Three internationally recognised Australasian contract research companies aim to expand their global market share by joining forces to attract biotech, pharmaceutical and medical device companies to Australia and New Zealand.

Clinical Network Services (CNS) and CPR Pharma Services (CPR) based in Brisbane and Adelaide, Australia, respectively, and **BELTAS™**, in Auckland, New Zealand, have formed a strategic partnership, named Trialliance.

Trialliance will launch its new brand **Fast2First™** at BioEurope 2010 in Munich 15-17 November. CNS CEO and founder Prof Tony (AJ) Webber says the partnership will allow companies to take advantage of the regulatory systems of Australia and New Zealand.

“The start up and execution of clinical trials is a critical milestone for many companies in our target markets, such as the USA and Europe. The formation of Trialliance and the launch of **Fast2First™** will enable them to complete these phases more quickly,” he says.

““Our region is best-placed globally to conduct clinical trials that deliver results to the highest quality in a timeline unparalleled in the traditional clinical centres in the Northern Hemisphere.”

Gerard Dunne, **BELTAS™** Managing Director says alignment of the three companies will add tremendous value for all clients as each is driven by very similar philosophies regarding customer service.

“Each of us has core areas of strength. We will be leveraging this depth and diversity, and matching our competencies with our countries’ pragmatic regulatory systems. This will add tangible value, particularly in early phase human testing, where we help our clients to realise faster go or no-go decisions.”

Jason Valentine CPR Pharma Services CEO says partnerships in the contract research industry are becoming more prevalent and the launch of Trialliance is a perfect example of why. “I look forward to growth of all three companies as a result of the expanded services this partnership provides.”

Fast2First™ has access to a network of Phase 1 units, clinics and hospitals across two countries and a suite of services unmatched in the region for clinical trials.

The combination of clinical and data management services coupled with a GLP bio-analytical laboratory means the **Fast2First™** service can deliver a suite of services. These can take a company seamlessly from initial first-in-human trials through to phase 3, the final clinical trials needed for commercialisation, with a single point of contact and one master service agreement.

“This kind of relationship efficiency and decreased administrative burden is increasingly demanded by companies which to date have had to look to larger, global CROs (Contract Research Organisations) to achieve this”, noted Russell Neal, Chief Operating Officer at CNS.

“When coupled with the fundamental regulatory advantages in the region, **Fast2First™** presents a refreshing refocus on the needs of biotech, pharma and device firms as the markets recover from the investment crunch of the last two years”.

About CNS

Clinical Network Services (CNS) Pty Ltd is a full-service Australian CRO, specialising in Phase I and Phase II clinical development. CNS is dedicated to providing innovative, solution-driven clinical trial management services to the international Biotech/BioPharma community. Over the last 12 years, CNS has managed more than 120 Australian and New Zealand-based clinical trials for over seventy US, European and Australian companies.

CNS is focused on supporting small start-up to medium-sized biotech/biopharma companies. This has resulted in a sound understanding of the sector's commercial goals, milestones and challenges. CNS has a track record of delivering on those needs through access to the strategically advantageous **Fast2First™** rapid study start-up and implementation service; its extensive network of phase I units and specialist hospital groups as well as its extensive, established global network of strategic CRO partners.

About BELTAS™

BELTAS™ is an award-winning Clinical Research Organisation (CRO) founded in New Zealand, with operations in New Zealand, Australia and Europe. **BELTAS™** CRO manages clinical trials for pharmaceutical, biotechnology and medical device companies,

About CPR Pharma Services

CPR Pharma Services was established in 2009. It is based in Adelaide, South Australia. CPR is a specialist early phase CRO providing project management, monitoring and report- writing services within its clinical team. It also offers early phase data management and biometrics and a GLP bio-analytical laboratory services. This unique suite of services, coupled with excellent relationships with phase 1 units and hospitals in Australia, sees CPR play a significant role in early phase clinical trials in the region.

- ends -

Media Contacts

Australia

Russell Neal
Chief Operating Officer
Clinical Network Services (CNS) Pty Ltd
+61 7 3719 6000
bne@fast2first.com

New Zealand

Gerard Dunne
Managing Director
BELTAS™ Ltd
+64 9 520 2410
akl@fast2first.com

www.fast2first.com

Ends